All In Biotech

NDA 221093 · Avyxa Holdings

Oxderys

Doxorubicin Hydrochloride · Multidose

Last checked: Nov 21, 2026Latest source record: Nov 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Nov 9, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,823

757 Phase 3, 308 recruiting

FAERS reports

26,045

24,961 serious, 4,432 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION Cardiomyopathy: Myocardial damage, including acute left ventricular failure, can occur with OXDERYS. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m 2 to 500 mg/m 2 when OXDERYS is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with OXDERYS [see Warnings and Precautions (5.1) ] . Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including OXDERYS [see Warnings and Precautions (5.2) ] ....

What it is approved for

From the label in effect Nov 12, 2026.

OXDERYS is an anthracycline topoisomerase inhibitor indicated: as a component of multi‑agent adjuvant chemotherapy for treatment of adults with axillary lymph node involvement following resection of primary breast cancer. ( 1.1 ) for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma. ( 1.2 ) 1.1 Adjuvant Breast Cancer OXDERYS is indicated as a component of multi-agent adjuvant chemotherapy for treatment of adults with axillary lymph node involvement following resection of primary breast cancer . 1.2 Other Cancers OXDERYS is indicated for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma (NHL) metastatic breast cancer metastatic Wilms' tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma

Mechanism: The cytotoxic effect of doxorubicin hydrochloride on malignant cells and its toxic effects on various organs are thought to be related to nucleotide base intercalation and cell membrane lipid binding activities of doxorubicin. Intercalation inhibits nucleotide replication and action of DNA and RNA polymerases. The interaction of doxorubicin with topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of doxorubicin hydrochloride cytocidal activity.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 9, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetter
2 products under this application
  • OXDERYS · DOXORUBICIN HYDROCHLORIDE 160MG/80ML (2MG/ML) · VIAL, MULTIDOSE · Prescription
  • OXDERYS · DOXORUBICIN HYDROCHLORIDE 40MG/20ML (2MG/ML) · VIAL, MULTIDOSE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxorubicin" as an intervention, any sponsor and status, largest first.

All 2,823 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use3,556
  • febrile neutropenia3,192
  • neutropenia1,978
  • product use in unapproved indication1,597
  • disease progression1,570
  • pyrexia1,559
  • anaemia1,264
  • nausea1,254
  • thrombocytopenia1,093
  • vomiting1,048
  • diarrhoea975
  • drug ineffective892

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004153
2005198
2006192
2007375
2008386
2009161
2010206
2011407
2012594
2013512
2014396
2015796
2016861
20171,028
20181,288
20191,453
20202,114
20211,729
20222,983
20233,234
20242,877
20252,351
20261,751

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,621 on PubMed

Sponsor: Avyxa Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.